Skip to content
Sexuality – Lifestyle
Author:
Immunic, Inc.
Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis
May 28, 2026
Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer
May 27, 2026
Immunic Appoints Seasoned Biopharmaceutical Executive Michael W. Bonney as Chair of the Board of Directors
May 19, 2026
Immunic to Participate in Investor and Medical Conferences in May
April 30, 2026
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
April 28, 2026
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
April 23, 2026
Immunic to Participate in Scientific and Medical Conferences in April
April 9, 2026
Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement
April 1, 2026
Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton
March 31, 2026
Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium
March 10, 2026